MX2022002270A - Vacunas contra el virus de la hepatitis b. - Google Patents
Vacunas contra el virus de la hepatitis b.Info
- Publication number
- MX2022002270A MX2022002270A MX2022002270A MX2022002270A MX2022002270A MX 2022002270 A MX2022002270 A MX 2022002270A MX 2022002270 A MX2022002270 A MX 2022002270A MX 2022002270 A MX2022002270 A MX 2022002270A MX 2022002270 A MX2022002270 A MX 2022002270A
- Authority
- MX
- Mexico
- Prior art keywords
- hbv
- polypeptides
- vaccines
- methods
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a polinucleótidos y polipéptidos aislados y vacunas relacionadas con el virus de la hepatitis B (VHB). La presente invención también se refiere a vectores virales para expresar esos polipéptidos, y que pueden usarse en vacunas contra el VHB, así como a métodos para proteger a un sujeto de la infección por VHB y a métodos para tratar el VHB en un sujeto que comprenden administrar los polipéptidos, vectores o vacunas descritos en este documento. También se proporcionan en este documento métodos para diseñar y producir una vacuna contra el VHB que comprenden diseñar antígenos de vacuna para cubrir la diversidad dentro de un área geográfica usando una secuencia de aminoácidos de antígeno que cubre eficientemente los epítopos en los genotipos de VHB presentes en el área geográfica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962893546P | 2019-08-29 | 2019-08-29 | |
US201962941125P | 2019-11-27 | 2019-11-27 | |
PCT/US2020/048411 WO2021045969A1 (en) | 2019-08-29 | 2020-08-28 | Hepatitis b virus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002270A true MX2022002270A (es) | 2022-03-22 |
Family
ID=74096044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002270A MX2022002270A (es) | 2019-08-29 | 2020-08-28 | Vacunas contra el virus de la hepatitis b. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220288195A1 (es) |
EP (1) | EP4021923A1 (es) |
JP (1) | JP2022545530A (es) |
KR (1) | KR20220090497A (es) |
CN (1) | CN114729010A (es) |
AU (1) | AU2020342385A1 (es) |
BR (1) | BR112022003474A2 (es) |
CA (1) | CA3149415A1 (es) |
IL (1) | IL290924A (es) |
MX (1) | MX2022002270A (es) |
WO (1) | WO2021045969A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60027581T2 (de) * | 1999-10-08 | 2007-05-10 | Celltech Pharma Europe Ltd., Slough | Design von immunogene |
DK1294893T3 (da) * | 2000-06-22 | 2006-07-03 | Ucb Pharma Ltd | Modifikation af hepatitis B-kerneantigen |
ES2315405T3 (es) * | 2001-05-25 | 2009-04-01 | Dobeel Corp. | Proteina pre-s del virus de la hepatitis b (vhb) como adyuvante y un componente de una vacuna frente a vhb. |
KR20130049210A (ko) * | 2003-10-21 | 2013-05-13 | 멜버른 헬스 | Hbv 변이체 검출 및 응용 |
AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
MX2012001592A (es) * | 2009-08-07 | 2012-05-22 | Transgene Sa | Composicion para el tratamiento de la infección del virus de la hepatitis b. |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
KR101418836B1 (ko) * | 2012-04-05 | 2014-08-13 | 서울대학교산학협력단 | 간질환 진단용 마커 및 이의 용도 |
AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
EP3402888B1 (en) * | 2016-01-12 | 2020-08-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating hbv |
-
2020
- 2020-08-28 MX MX2022002270A patent/MX2022002270A/es unknown
- 2020-08-28 AU AU2020342385A patent/AU2020342385A1/en active Pending
- 2020-08-28 CA CA3149415A patent/CA3149415A1/en active Pending
- 2020-08-28 KR KR1020227009774A patent/KR20220090497A/ko unknown
- 2020-08-28 BR BR112022003474A patent/BR112022003474A2/pt unknown
- 2020-08-28 US US17/638,344 patent/US20220288195A1/en active Pending
- 2020-08-28 JP JP2022513077A patent/JP2022545530A/ja active Pending
- 2020-08-28 WO PCT/US2020/048411 patent/WO2021045969A1/en active Application Filing
- 2020-08-28 EP EP20830016.0A patent/EP4021923A1/en active Pending
- 2020-08-28 CN CN202080061230.2A patent/CN114729010A/zh active Pending
-
2022
- 2022-02-27 IL IL290924A patent/IL290924A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022545530A (ja) | 2022-10-27 |
CN114729010A (zh) | 2022-07-08 |
US20220288195A1 (en) | 2022-09-15 |
CA3149415A1 (en) | 2021-03-11 |
AU2020342385A1 (en) | 2022-03-31 |
IL290924A (en) | 2022-04-01 |
WO2021045969A1 (en) | 2021-03-11 |
BR112022003474A2 (pt) | 2022-05-24 |
EP4021923A1 (en) | 2022-07-06 |
KR20220090497A (ko) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550580A1 (en) | African swine fever virus vaccine | |
PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
EA201990085A1 (ru) | Рационально разработанный аттенуированный штамм вируса африканской лихорадки свиней для защиты от заражения исходным вирусным изолятом georgia 2007 | |
MX2022002270A (es) | Vacunas contra el virus de la hepatitis b. | |
EA202091513A1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
MX2020011802A (es) | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. | |
ZA202104213B (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
RU2015155821A (ru) | Вакцины против малярии | |
WO2017044895A3 (en) | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF | |
CA3010977A1 (en) | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus | |
AU2018388102A1 (en) | Cross-immunizing antigen vaccine and method for preparation thereof | |
WO2014128568A3 (en) | Compositions and methods for treatment of hepatitis c | |
PH12017500419A1 (en) | Recoded arbovirus and vaccines | |
GB2429711A (en) | Heart and skeletal muscle inflammation (HSMI) virus | |
PH12020551944A1 (en) | Reverse peptide vaccine | |
MX2019007924A (es) | Vacunas contra la influenza. | |
RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
EA202091177A1 (ru) | Композиции и схема иммунизации против гепатита b | |
Zhu et al. | Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160 | |
WO2006113927A3 (en) | Immunogenic vaccinia peptides and methods of using same | |
WO2019106432A3 (en) | Viral vector constructs for expression of genetic adjuvants mimicking cd40 signaling | |
RU2018114583A (ru) | Перекрестно-реактивные t-клеточные эпитопы вич, siv и fiv для вакцин у человека и кошек | |
WO1999015692A3 (en) | Dengue virus antigens and treatment of dengue fever | |
WO2016055963A1 (en) | Construction of immunogenic synthetic oligopeptides |